Characterizing the mechanisms of progression in multiple sclerosis

Evidence and new hypotheses for future directions

E. M. Frohman, M. Filippi, O. Stuve, S. G. Waxman, J. Corboy, J. T. Phillips, C. Lucchinetti, J. Wilken, N. Karandikar, B. Hemmer, N. Monson, J. De Keyser, H. Hartung, L. Steinman, J. R. Oksenberg, B. A C Cree, S. Hauser, M. K. Racke

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.

Original languageEnglish
Pages (from-to)1345-1356
Number of pages12
JournalArchives of Neurology
Volume62
Issue number9
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Multiple Sclerosis
Direction compound
Progression
Therapeutics
Research

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Characterizing the mechanisms of progression in multiple sclerosis : Evidence and new hypotheses for future directions. / Frohman, E. M.; Filippi, M.; Stuve, O.; Waxman, S. G.; Corboy, J.; Phillips, J. T.; Lucchinetti, C.; Wilken, J.; Karandikar, N.; Hemmer, B.; Monson, N.; De Keyser, J.; Hartung, H.; Steinman, L.; Oksenberg, J. R.; Cree, B. A C; Hauser, S.; Racke, M. K.

In: Archives of Neurology, Vol. 62, No. 9, 09.2005, p. 1345-1356.

Research output: Contribution to journalArticle

Frohman, EM, Filippi, M, Stuve, O, Waxman, SG, Corboy, J, Phillips, JT, Lucchinetti, C, Wilken, J, Karandikar, N, Hemmer, B, Monson, N, De Keyser, J, Hartung, H, Steinman, L, Oksenberg, JR, Cree, BAC, Hauser, S & Racke, MK 2005, 'Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions', Archives of Neurology, vol. 62, no. 9, pp. 1345-1356. https://doi.org/10.1001/archneur.62.9.1345
Frohman, E. M. ; Filippi, M. ; Stuve, O. ; Waxman, S. G. ; Corboy, J. ; Phillips, J. T. ; Lucchinetti, C. ; Wilken, J. ; Karandikar, N. ; Hemmer, B. ; Monson, N. ; De Keyser, J. ; Hartung, H. ; Steinman, L. ; Oksenberg, J. R. ; Cree, B. A C ; Hauser, S. ; Racke, M. K. / Characterizing the mechanisms of progression in multiple sclerosis : Evidence and new hypotheses for future directions. In: Archives of Neurology. 2005 ; Vol. 62, No. 9. pp. 1345-1356.
@article{8d9923d057e248268f32a9556aa15904,
title = "Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions",
abstract = "Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.",
author = "Frohman, {E. M.} and M. Filippi and O. Stuve and Waxman, {S. G.} and J. Corboy and Phillips, {J. T.} and C. Lucchinetti and J. Wilken and N. Karandikar and B. Hemmer and N. Monson and {De Keyser}, J. and H. Hartung and L. Steinman and Oksenberg, {J. R.} and Cree, {B. A C} and S. Hauser and Racke, {M. K.}",
year = "2005",
month = "9",
doi = "10.1001/archneur.62.9.1345",
language = "English",
volume = "62",
pages = "1345--1356",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Characterizing the mechanisms of progression in multiple sclerosis

T2 - Evidence and new hypotheses for future directions

AU - Frohman, E. M.

AU - Filippi, M.

AU - Stuve, O.

AU - Waxman, S. G.

AU - Corboy, J.

AU - Phillips, J. T.

AU - Lucchinetti, C.

AU - Wilken, J.

AU - Karandikar, N.

AU - Hemmer, B.

AU - Monson, N.

AU - De Keyser, J.

AU - Hartung, H.

AU - Steinman, L.

AU - Oksenberg, J. R.

AU - Cree, B. A C

AU - Hauser, S.

AU - Racke, M. K.

PY - 2005/9

Y1 - 2005/9

N2 - Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.

AB - Major advancements have been achieved in our ability to diagnose multiple sclerosis (MS) and to commence treatment intervention with agents that can favorably affect the disease course. Although MS exacerbations and the emergence of disability constitute the more conspicuous aspects of the disease process, evidence has confirmed that most of the disease occurs on a constitutive and occult basis. Disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive stage of the disease. Therapeutic strategies currently used for MS primarily target the inflammatory cascade. Several potential mechanisms appear to be involved in the progression of MS. Characterizing these mechanisms will result in a better understanding of the various forms of the disorder and how to effectively treat its clinical manifestations. It is our objective within this 2-part series on progression in MS to offer both evidence-based observations and hypothesis-driven expert perspectives on what constitutes the cause of progression in MS. We have chosen areas of inquiry that appear to have been most productive in helping us to better conceptualize the landscape of what MS looks like pathologically, immunologically, neuroscientifically, radiographically, and genetically. We have attempted to advance hypotheses focused on a deeper understanding of what contributes to the progression of this illness and to illustrate new technical capabilities that are catalyzing novel research initiatives targeted at achieving a more complete understanding of progression in MS.

UR - http://www.scopus.com/inward/record.url?scp=25144520110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144520110&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.9.1345

DO - 10.1001/archneur.62.9.1345

M3 - Article

VL - 62

SP - 1345

EP - 1356

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -